Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Breast Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 4Lymphoma, Mantle-Cell 4Colorectal Neoplasms 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Waldenstrom Macroglobulinemia 2Squamous Cell Carcinoma of Head and Neck 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasms 2Multiple Myeloma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Prolymphocytic 2Leukemia, Myeloid, Acute 2Leukemia 2Hodgkin Disease 2Gliosarcoma 2Glioma 2Congenital Abnormalities 2Colonic Neoplasms 2Burkitt Lymphoma 2

Interventions

Rituximab 77Cyclophosphamide 54fludarabine phosphate 50Peripheral Blood Stem Cell Transplantation 44Mycophenolic Acid 34Whole-Body Irradiation 33Tacrolimus 25Cyclosporine 23Busulfan 22Bortezomib 22Dexamethasone 21Etoposide 19ibrutinib 18Melphalan 17Antilymphocyte Serum 17Methotrexate 15Lenalidomide 15Filgrastim 14Radiotherapy 12Bendamustine Hydrochloride 12Sirolimus 10Calcium Dobesilate 10Flow Cytometry 9Everolimus 9Cyclosporins 9zanubrutinib 8Alemtuzumab 7ibritumomab tiuxetan 6Transplantation 6Therapeutics 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Waldenstrom Macroglobulinemia × Pharmacogenomic Testing × Clear all
NCT01479842 2026-03-23

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Active not recruiting
48 enrolled
Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01129193 2018-06-04

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
44 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡